Kev piav qhia
Peb tofacitinib intermediate tseem hu ua cis-1-benzyl-4-methyl-3-methylaminopiperidine dihydrochloride thiab muaj CAS naj npawb 1062580-52-2.Qhov nruab nrab yog cov khoom tseem ceeb hauv kev tsim cov tofacitinib, ib qho tshuaj siv los kho mob rheumatoid mob caj dab, psoriatic mob caj dab thiab ulcerative colitis.Raws li cov intermediates tseem ceeb nyob rau hauv cov synthesis ntawm tofacitinib, peb cov khoom yog ib qho tseem ceeb rau cov kws tshawb fawb thiab manufacturers.
Qhov kev sib xyaw nruab nrab no tau ua tib zoo ua ke kom ntseeg tau tias qib siab tshaj plaws ntawm purity thiab sib xws.Nrog peb cov txheej txheem tsim khoom hauv lub xeev thiab kev tswj xyuas nruj, koj tuaj yeem ntseeg tau tias peb cov tofacitinib intermediates ua tau raws li cov qauv kev lag luam siab tshaj plaws rau purity thiab ruaj khov.
Tofacitinib Intermediate (3R, 4R) -1-Benzyl-3- (Mmethylamino) -4-Mmethylpiperidine DiHClide muaj ntau yam kev siv, ua rau nws muaj txiaj ntsig zoo hauv kev tshawb fawb tshuaj thiab tshuaj.Txawm hais tias koj tab tom nrhiav kev tshawb fawb los yog tsim cov tshuaj, peb cov khoom siv nruab nrab muab cov kev daws teeb meem zoo thiab muaj txiaj ntsig rau koj cov kev xav tau tshwj xeeb.
Xaiv Peb
JDK muaj cov chaw tsim khoom thawj zaug thiab cov cuab yeej tswj kev ua haujlwm zoo, uas ua kom muaj kev ruaj khov ntawm API intermediates.Pab neeg tshaj lij paub tseeb R & D ntawm cov khoom.Tawm tsam ob qho tib si, peb tab tom nrhiav rau CMO & CDMO hauv kev lag luam hauv tsev thiab thoob ntiaj teb.